--- title: "Pharmacodynamic effects: interferon-beta-1a in MS | Sutter Health" description: "A strong pharmacodynamic effect of interferon-beta-1a in multiple sclerosis was observed 1.5 (short-term) vs. 6 days post weekly injection." url: "https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Pharmacodynamic effects: interferon-beta-1a in MS # Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. Kantor AB, Deng J, Waubant E, Lin H, Becker CH, Lacy JR, Perrone AM, Bennett D, & Goelz SE. _J Neuroimmunol. 188(1-2):103-16. Epub 2007 Jul 5._ 2007-08-01 ## Abstract We applied broad-based phenotypic profiling to identify pharmacodynamic markers for interferon-beta in multiple sclerosis subjects. A strong pharmacodynamic effect was observed 1.5 (short-term) vs. 6 days post weekly injection. Hundreds of differences were observed at a p-value <0.001. Most major cell populations, including neutrophils, B cells, CD4 T cells and CD8 T cells, decreased in absolute counts at 1.5 days. The striking exception was monocytes, which increased substantially. Changes in multiple monocyte-associated cell surface molecules and monocyte related soluble factors were also observed, including: HLA class II, CCR5, CD38, CD40, CD54, CD64, CD69, CD86, CD101, TLR2, TLR4 and MCP2. These results demonstrate that new hypotheses can be generated from broad molecular and cellular profiling in a clinical setting and provide an approach to identify candidate pharmacodynamic markers to evaluate new drug formulations, dosing and bioequivalence. [PubMed abstract](https://www.ncbi.nlm.nih.gov/pubmed/17614141) ## Research topics - [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22) - [Neurological Disorders](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Neurological+Disorders%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Interferon beta-1a in children with multiple sclerosis is well tolerated.](https://www.sutterhealth.org/research/publications/interferon-beta-1a-children-ms-tolerance-1055312304) Waubant E, Hietpas J, Stewart T, Dyme Z, Herbert J, Lacy J, Miller C, Rensel M, Schwid S, Goodkin D. Neuropediatrics. 32(4):211-3. 2001 Aug 01 - Publication ### [Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation.](https://www.sutterhealth.org/research/publications/chronic-demyelinate-polyneuropathy-lymph-radiation-1055312345) Rosenberg NL, Lacy JR, Kennaugh RC, Holers VM, Neville HE, Kotzin BL. Muscle Nerve. 8(3):223-32. 1985 Mar 01 - Publication ### [Rethinking STOP-ROP: Is it worthwhile trying to modulate excessive VEGF levels in prethreshold ROP eyes by systemic intervention? A review of the role of oxygen, light adaptation state, and anemia in prethreshold ROP.](https://www.sutterhealth.org/research/publications/modulate-vegf-levels-prethreshold-rop-eyes-1055312982) Gaynon MW. Retina. 26(7 Suppl):S18-23. 2006 Sep 01 - Publication ### [Electronic health record technology designed for the clinical encounter: MS NeuroShare](https://www.sutterhealth.org/research/publications/ms-neuroshare-1055312826) Bove R, Bruce CA, Lunders CK, Pearce JR, Liu J, Schleimer E, Hauser SL, Stewart WF, Jones JB. Neurol Clin Pract.(4):318-326. doi: 10.1212/CPJ.0000000000000986. 2021 Aug 11 - Publication ### [Analyses of nursing home residents with multiple sclerosis and depression using the Minimum Data Set.](https://www.sutterhealth.org/research/publications/nursing-home-residents-ms-depression-1055312585) Buchanan RJ, Wang S, Tai-Seale M, Ju H. Mult Scler. 9(2):171-88. 2003 Mar 01 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Pharmacodynamic effects: interferon-beta-1a in MS"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290#medicalscholarlyarticle","name":"Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling.","headline":"Pharmacodynamic effects: interferon-beta-1a in MS","abstract":"We applied broad-based phenotypic profiling to identify pharmacodynamic markers for interferon-beta in multiple sclerosis subjects. A strong pharmacodynamic effect was observed 1.5 (short-term) vs. 6 days post weekly injection. Hundreds of differences were observed at a p-value \u003c0.001. Most major cell populations, including neutrophils, B cells, CD4 T cells and CD8 T cells, decreased in absolute counts at 1.5 days. The striking exception was monocytes, which increased substantially. Changes in multiple monocyte-associated cell surface molecules and monocyte related soluble factors were also observed, including: HLA class II, CCR5, CD38, CD40, CD54, CD64, CD69, CD86, CD101, TLR2, TLR4 and MCP2. These results demonstrate that new hypotheses can be generated from broad molecular and cellular profiling in a clinical setting and provide an approach to identify candidate pharmacodynamic markers to evaluate new drug formulations, dosing and bioequivalence.","description":"A strong pharmacodynamic effect of interferon-beta-1a in multiple sclerosis was observed 1.5 (short-term) vs. 6 days post weekly injection.","keywords":["Disease Management","Neurological Disorders"],"datePublished":"2007-08-01","url":"https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"17614141"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/17614141/"],"isPartOf":{"@type":"Periodical","name":"J Neuroimmunol"},"author":[{"@type":"Person","name":"Kantor AB"},{"@type":"Person","name":"Deng J"},{"@type":"Person","name":"Waubant E"},{"@type":"Person","name":"Lin H"},{"@type":"Person","name":"Becker CH"},{"@type":"Person","name":"Lacy JR"},{"@type":"Person","name":"Perrone AM"},{"@type":"Person","name":"Bennett D"},{"@type":"Person","name":"Goelz SE"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Neurological Disorders","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Neurological+Disorders%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/pharmacodynamic-effects-interferon-beta-1a-ms-1055312290#breadcrumblist"}}} ```